Resistance to BRAF Inhibition in Melanomas
Top Cited Papers
- 24 February 2011
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 364 (8), 772-774
- https://doi.org/10.1056/nejmcibr1013704
Abstract
PLX4032, an inhibitor of activated BRAF, has shown clinical efficacy in treating patients with melanomas carrying an activating mutation in BRAF, but resistance to the drug develops in some patients. Two recent studies show possible mechanisms of such resistance.Keywords
This publication has 8 references indexed in Scilit:
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaNew England Journal of Medicine, 2010
- Gatekeeper Mutations Mediate Resistance to BRAF-Targeted TherapiesScience Translational Medicine, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in MelanomaCancer Research, 2008